Zhitong Finance App News, ST Renfu (600079.SH) announced that RFUS-949 tablets developed by the company's holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) have recently entered phase II clinical trial research. Test name: Evaluating the efficacy and safety of RFUS-949 tablets for post-operative analgesia after abdominal surgery The purpose of the trial is to evaluate the efficacy and safety of RFUS-949 tablets for post-operative analgesia and explore the usage and dosage of RFUS-949 tablets for postoperative analgesia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.